-
EP3962957
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3962957
| EP3962957 - ASSOCIATION OF POLYCLONAL ANTIBODIES AND ANTI-PD1 OR ANTI-PDL1 ANTIBODIES FOR THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.10.2024 Database last updated on 12.10.2024 | |
| Former | Request for examination was made Status updated on 04.02.2022 | ||
| Former | The international publication has been made Status updated on 06.11.2020 | ||
| Former | unknown Status updated on 12.05.2020 | Most recent event Tooltip | 09.10.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Xenothera 1 rue Vauban 44000 Nantes / FR | [2022/10] | Inventor(s) | 01 /
DUVAUX, Odile Xenothera 1 rue Vauban 44000 Nantes / FR | 02 /
VANHOVE, Bernard Xenothera 1 rue Vauban 44000 Nantes / FR | [2022/10] | Representative(s) | Cabinet Nony 11 rue Saint-Georges 75009 Paris / FR | [N/P] |
| Former [2022/10] | Nony 11 rue Saint-Georges 75009 Paris / FR | Application number, filing date | 20723066.5 | 28.04.2020 | [2022/10] | WO2020EP61710 | Priority number, date | EP20190305556 | 30.04.2019 Original published format: EP 19305556 | [2022/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020221723 | Date: | 05.11.2020 | Language: | EN | [2020/45] | Type: | A1 Application with search report | No.: | EP3962957 | Date: | 09.03.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.11.2020 takes the place of the publication of the European patent application. | [2022/10] | Search report(s) | International search report - published on: | EP | 05.11.2020 | Classification | IPC: | C07K16/30, C07K16/28, A61P35/00 | [2022/10] | CPC: |
C07K16/3076 (EP,US);
C07K16/2818 (EP,US);
A61P35/00 (EP,US);
C07K16/2827 (EP,US);
A61K2039/507 (EP,US);
C07K2317/41 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/10] | Title | German: | ASSOZIATION VON POLYKLONALEN ANTIKÖRPERN UND ANTI-PD1- ODER ANTI-PDL1-ANTIKÖRPERN ZUR BEHANDLUNG VON KREBS | [2022/10] | English: | ASSOCIATION OF POLYCLONAL ANTIBODIES AND ANTI-PD1 OR ANTI-PDL1 ANTIBODIES FOR THE TREATMENT OF CANCER | [2022/10] | French: | ASSOCIATION D'ANTICORPS POLYCLONAUX ET D'ANTICORPS ANTI-PD1 OU ANTI-PDL1 POUR LE TRAITEMENT DU CANCER | [2022/10] | Entry into regional phase | 30.11.2021 | National basic fee paid | 30.11.2021 | Designation fee(s) paid | 30.11.2021 | Examination fee paid | Examination procedure | 20.10.2021 | Amendment by applicant (claims and/or description) | 30.11.2021 | Examination requested [2022/10] | 30.11.2021 | Date on which the examining division has become responsible | 08.10.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 02.05.2022 | Renewal fee patent year 03 | 02.05.2023 | Renewal fee patent year 04 | 24.04.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2013114367 (COMPUGEN LTD [IL]); | [A]EP3207055 (XENOTHERA [FR]); | by applicant | EP0335804 | JPH07155194 | US6870034 | EP1601697 | WO2006133356 | US7547816 | WO2010094901 |